CGIM
CYTK icon

Cannon Global Investment Management’s Cytokinetics CYTK Stock Holding History

Cannon Global Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,000
Closed -$241K – 87
2025
Q1 		$241K Buy
+6,000
New +$276K 0.42% 55
2024
Q2 		– Sell
-9,700
Closed -$680K – 46
2024
Q1 		$680K Buy
+9,700
New +$750K 1.83% 13

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Cannon Global Investment Management's CYTK Position: Q2 2025 in Review

Cannon Global Investment Management sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 6,000 shares — an estimated $241K sold.

Cannon Global Investment Management first reported a position in CYTK in Q1 2024 and held it in 2 quarters. The position peaked at $680K in Q1 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • Cannon Global Investment Management reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 6,000 Cytokinetics shares in Q2 2025, an estimated $241K.
  • Cannon Global Investment Management first reported a position in Cytokinetics in Q1 2024 and held it in 2 quarters.
  • Cannon Global Investment Management's Cytokinetics position peaked at $680K in Q1 2024.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Cannon Global Investment Management's 13F filing for Q2 2025, filed 29 Jul 2025.